Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

ConclusionThese results support dupilumab as continuous long-term treatment for adults with moderate-to-severe AD; efficacy was sustained following transition from qw to q2w dosing.Trial Registration ClinicalTrials.govNCT01949311.
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research